Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut microbiota depletion and immune response during human endotoxemia
NL-OMON27487Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2014
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lipopolysaccharide endotoxin, ciprofloxacin, vancomycin and metronidazole (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Inflammatory laboratory response parameters, Functional immune assays and 1 more. Started Apr 2014; status: active, not recruiting.
02
Drugs
lipopolysaccharide endotoxinciprofloxacinvancomycinmetronidazole
Beyond the preview
Go deeper on NL-OMON27487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27487.